A review of immunosuppressive therapy in the context of uterine VCA and pregnancy
Frontiers in Transplantation · 06.07.2026 · 5
DOI: 10.3389/frtra.2026.1825928 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Transplantation, online erschienen am 06.07.2026. Verfasst von Andrew D'Elia und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Plastic, Reconstructive and Aesthetic Surgery, Department of Surgery, University of Toronto, Toronto, ON, Canada. Die Arbeit nennt 162 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Uterine vascularized composite allotransplantation (VCA) represents one of the latest developments in the field of transplant surgery and treatment of uterine-factor infertility. Unlike other forms of VCA, uterine transplantation involves a temporary allograft, pregnancy-associated physiologic and pharmacokinetic changes, and complex maternal–fetal immunologic interactions, creating distinct challenges in immunosuppression management. Herein, we perform a comprehensive review of the latest and relevant literature on immunosuppressive strategies in the context of VCA and pregnancy, with particular emphasis on their relevance to uterine VCA. Evidence from solid organ transplantation, autoimmune disease, and reported uterine transplant protocols was synthesized to inform stage-specific management strategies. Available data support corticosteroids, calcineurin inhibitors, azathioprine, and hydroxychloroquine as pregnancy-compatible agents, whereas mycophenolate mofetil, methotrexate, and cyclophosphamide remain contraindicated due to teratogenicity. Pregnancy-related pharmacokinetic and pharmacodynamic changes significantly influence drug exposure and necessitate individualized dosing and close therapeutic monitoring. Emerging evidence suggests that pregnancy-associated immune modulation, including regulatory T-cell expansion and microchimerism, may reduce rejection risk, although this remains incompletely characterized. Based on best available evidence, we present a summary for immunosuppressive management spanning induction, preconception optimization, pregnancy, delivery, and postpartum graft removal. Future priorities include development of noninvasive rejection monitoring, precision pharmacokinetic modeling, and tolerance-inducing strategies to improve maternal, fetal, and allograft outcomes in uterine transplantation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Plastic, Reconstructive and Aesthetic Surgery, Department of Surgery, University of Toronto, Toronto, ON, Canada.
- Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
- Toronto Western Hospital, University Health Network, Toronto, ON, Canada.
Zitieren
APA
D'Elia, A., Ghajar, K., & Zuo, K. J. (2026). A review of immunosuppressive therapy in the context of uterine VCA and pregnancy. Frontiers in Transplantation, 5. https://doi.org/10.3389/frtra.2026.1825928
Vancouver
D'Elia A, Ghajar K, Zuo KJ. A review of immunosuppressive therapy in the context of uterine VCA and pregnancy. Frontiers in Transplantation. 2026;5. doi:10.3389/frtra.2026.1825928
BibTeX
@article{DElia2026,
author = {D'Elia, Andrew and Ghajar, Kevin and Zuo, Kevin J},
title = {A review of immunosuppressive therapy in the context of uterine VCA and pregnancy},
journal = {Frontiers in Transplantation},
year = {2026},
volume = {5},
doi = {10.3389/frtra.2026.1825928}
}
EUVIMED